CollaGenex Pharmaceuticals to Host Second Quarter and First Half of 2007 Financial Results Conference Call on August 7th
Collagenex Pharmaceuticals zu myNews hinzufügen Was ist das?
CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it
will hold a conference call on Tuesday, August 7, 2007, at 11:00 a.m.
Eastern Time to discuss the Company's second quarter and first half 2007
financial results. A press release announcing the Company's financial
results will be released before the market opens on Tuesday, August 7,
2007.
Colin Stewart, president and chief executive officer of CollaGenex, and
Nancy C. Broadbent, chief financial officer of CollaGenex, will host the
conference call.
Investors and other interested parties may access the conference call by
dialing (888) 694-4728 in the U.S. or (973) 582-2745 internationally, or
via a live webcast on the Company's website at www.collagenex.com.
For those who cannot listen to the live broadcast, a replay will be
available shortly after the call at www.collagenex.com
for 90 days. Additionally, a recording of the call will be available by
telephone until 11:59 p.m. on August 14, 2007 by dialing (877) 519-4471
in the U.S. or (877) 519-4471 internationally, and entering access code:
9051755.
About CollaGenex
CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company
currently focused on developing and marketing proprietary, innovative
medical therapies to the dermatology market. In July 2006, CollaGenex
launched Oracea(R), the first FDA-approved systemic product for the
treatment of rosacea. CollaGenex's professional dermatology sales force
also markets Pandel, a prescription topical corticosteroid licensed from
Altana, Inc., Alcortin(R) (1% iodoquinol and 2% hydrocortisone), a
prescription topical antifungal steroid combination, and Novacort(R) (2%
hydrocortisone acetate and 1% pramoxine HCl), a prescription topical
steroid and anesthetic. Alcortin and Novacort are marketed by the
Company under a Promotion and Cooperation agreement with Primus
Pharmaceuticals, Inc. CollaGenex is conducting two Phase II dose-finding
studies to evaluate its second dermatology candidate, incyclinide, for
the treatment of acne and rosacea, respectively. CollaGenex is also
conducting Phase II clinical trials to evaluate COL-118, a topical
compound based on the SansRosa technology, for the treatment of redness
associated with rosacea and other skin disorders. CollaGenex recently
acquired the rights to develop and commercialize becocalcidiol, a
patented Vitamin D analogue developed by QuatRx Pharmaceuticals Company
that is currently in Phase II clinical trials for the topical treatment
of mild to moderate psoriasis.
Research has shown that compounds can be created by chemically modifying
certain tetracyclines and that these new compounds have properties that
may make them effective in treating diseases involving inflammation
and/or destruction of the body's connective tissues. CollaGenex is
evaluating various chemically modified tetracyclines (so called
"IMPACS"(TM) compounds because they are Inhibitors of Multiple Proteases
And CytokineS) to assess whether they are safe and effective in these
applications. The Company has a pipeline of innovative product
candidates with possible applications in dermatology and other disease
states. In addition, CollaGenex has acquired the SansRosa(TM)
technology, which consists of a class of compounds that have shown
promise in reducing the redness associated with rosacea, and the
Restoraderm(R) technology, a unique, proprietary dermal drug delivery
system. CollaGenex plans to leverage these platforms to develop a range
of topical dermatological products with enhanced pharmacologic and
cosmetic properties.
To receive additional information on the Company, please visit our
Website at www.collagenex.com,
which does not form part of this press release.
Periostat(R), Restoraderm(R) and Oracea(R) are registered trademarks
and IMPACS(TM) and SansRosa(TM) are trademarks of CollaGenex
Pharmaceuticals, Inc. Novacort(R) and Alcortin(R) are trademarks of Primus Pharmaceuticals,
Inc. Pandel(R) is a trademark of Taisho Pharmaceuticals. Atridox(R), Atrisorb(R) and Atrisorb-D(R) are registered trademarks
of Tolmar, Inc. All other trade names, trademarks or service marks are the property
of their respective owners and are not the property of CollaGenex
Pharmaceuticals, Inc. or any of our subsidiaries.
